ABVC Biopharma Files 8-K: Material Agreement & Equity Sales

TL;DR

ABVC Bio just dropped an 8-K on a big deal and equity sales - check the filings for details.

AI Summary

On January 6, 2025, ABVC Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. Specific details regarding the agreement, the equity sales, and the financial information are provided within the full document.

Why It Matters

This filing indicates significant corporate activity, including a new material agreement and the issuance of equity, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Registrant
• January 6, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-40700 (identifier) — Commission File Number
• 26-0014658 (identifier) — IRS Employer Identification No.
• 44370 Old Warm Springs Blvd. (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
• $0.75 — on Stock at a reduced exercise price of $0.75 per share. Lind also received a new war
• $1.00 — the five-year anniversary thereof, for $1.00 per share (the " May Warrant ", with al
• $0.42 — r share, at a reduced exercise price of $0.42 per share. On January 5, 2025, the Com
• $0.40 — r share, at a reduced exercise price of $0.40 per share. Other than the Outstanding E

Filing Documents

• ea0226487-8k_abvcbio.htm (8-K) — 28KB
• ea022648701ex10-1_abvcbio.htm (EX-10.1) — 29KB
• 0001213900-25-001211.txt ( ) — 235KB
• abvc-20250106.xsd (EX-101.SCH) — 3KB
• abvc-20250106_lab.xml (EX-101.LAB) — 33KB
• abvc-20250106_pre.xml (EX-101.PRE) — 22KB
• ea0226487-8k_abvcbio_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As previously reported, over the past year, ABVC BioPharma, Inc. (the " Company ") has entered into three securities purchase agreements with Lind Global Fund II, LP (" Lind "), pursuant to which the Company has issued to Lind: (i) 3,527,778 shares of the Company's common stock, par value $0.001 per share (the " Common Stock ") underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of February 23, 2023 between the Company and Lind (the " Lind Transaction "); (ii) 5,291,667 shares of Common Stock underlying a common stock purchase warrant pursuant to the Lind Transaction; (iii) 342,857 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of November 17, 2023 between the Company and Lind (the " 2 nd Lind Transaction "); (iv) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 2 nd Lind Transaction; (v) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the " 3 rd Lind Transaction ," together with the Lind Transaction and 2 nd Lind Transaction, the " Initial Lind Transactions ") and (vi) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3 rd Lind Transaction. On May 22, 2024, the Company and Lind entered into a letter agreement (the " May Letter Agreement "), pursuant to which Lind exercised, for cash, 1,000,000 of the Existing Warrants to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Lind also received a new warrant to purchase 1,000,000 shares Common Stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $1.00 per share (the " May Warrant ", with all of the w

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit 10.1 Letter Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. January 6, 2025 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR